clinical trial · NCT06839339
Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
Beijing Anlong Biopharmaceutical Co., Ltd.·phase2·not yet recruiting·n = 40
Wet Age-related Macular Degeneration (wAMD)AL-001Aflibercept
brief summary
This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will be randomized in Cohorts 1 and 2 to receive AL-001 administered via suprachoroidal space injection, Cohort 3 to receive Aflibercept.
started
Feb 18, 2025
primary completion
Sep 30, 2026
completion
Jan 30, 2027
last updated
Feb 21, 2025
official title
A Phase II, Randomized, Positive-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Single Suprachoroidal Space Injection of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Macular Degeneration (wAMD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol